AU2021333776A1 - Inhibitors of APOL1 and methods of using same - Google Patents

Inhibitors of APOL1 and methods of using same Download PDF

Info

Publication number
AU2021333776A1
AU2021333776A1 AU2021333776A AU2021333776A AU2021333776A1 AU 2021333776 A1 AU2021333776 A1 AU 2021333776A1 AU 2021333776 A AU2021333776 A AU 2021333776A AU 2021333776 A AU2021333776 A AU 2021333776A AU 2021333776 A1 AU2021333776 A1 AU 2021333776A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
optionally substituted
halogen
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021333776A
Other languages
English (en)
Inventor
Jun Myun AHN
Samantha ANGLE
Michael Aaron Brodney
Jingrong Cao
John E. Cochran
Jon H. Come
Leslie A. DAKIN
Elena DOLGIKH
Brad D. MAXWELL
Suganthini S. Nanthakumar
Jessica Howard OLSEN
Hardwin O’Dowd
Timothy J. SENTER
Akira Joseph SHIMIZU
Steven David STONE
Haoxuan WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2021333776A1 publication Critical patent/AU2021333776A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2021333776A 2020-08-26 2021-08-26 Inhibitors of APOL1 and methods of using same Pending AU2021333776A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070705P 2020-08-26 2020-08-26
US63/070,705 2020-08-26
PCT/US2021/047754 WO2022047031A1 (en) 2020-08-26 2021-08-26 Inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
AU2021333776A1 true AU2021333776A1 (en) 2023-03-16

Family

ID=77822053

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021333776A Pending AU2021333776A1 (en) 2020-08-26 2021-08-26 Inhibitors of APOL1 and methods of using same

Country Status (26)

Country Link
US (2) US11866446B2 (cg-RX-API-DMAC7.html)
EP (1) EP4204423B1 (cg-RX-API-DMAC7.html)
JP (2) JP7743504B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230057386A (cg-RX-API-DMAC7.html)
CN (1) CN116547287B (cg-RX-API-DMAC7.html)
AR (1) AR123355A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021333776A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023003423A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190609A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000536A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023003026A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230132A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000042A (cg-RX-API-DMAC7.html)
EC (1) ECSP23020167A (cg-RX-API-DMAC7.html)
FI (1) FI4204423T3 (cg-RX-API-DMAC7.html)
IL (2) IL300298B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20230035A1 (cg-RX-API-DMAC7.html)
LT (1) LT4204423T (cg-RX-API-DMAC7.html)
MA (1) MA61088B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002269A (cg-RX-API-DMAC7.html)
PE (1) PE20231106A1 (cg-RX-API-DMAC7.html)
PT (1) PT4204423T (cg-RX-API-DMAC7.html)
SA (1) SA523442662B1 (cg-RX-API-DMAC7.html)
TW (1) TWI915407B (cg-RX-API-DMAC7.html)
UY (1) UY39395A (cg-RX-API-DMAC7.html)
WO (1) WO2022047031A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4114385A1 (en) 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
KR20240051990A (ko) * 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
WO2024249252A1 (en) * 2023-05-26 2024-12-05 Maze Therapeutics, Inc. Methods of using apol1 inhibitors
CN122003420A (zh) 2023-09-11 2026-05-08 弗特克斯药品有限公司 用于制备(2s,4s,4's,6s)-2-甲基-6-(1-甲基-1h-1,2,3-三唑-4-基)-2'-(三氟甲基)-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]-4'-醇的方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
CA2262569A1 (en) 1996-08-09 1998-02-19 Norihito Ohi Benzopiperidine derivatives
WO2001017965A2 (en) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines as pesticides
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
WO2002028831A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
WO2003014732A1 (en) 2001-08-10 2003-02-20 Symyx Technologies, Inc. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
AU2004268919A1 (en) 2003-09-03 2005-03-10 Galapagos Nv Novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-HT2A receptor-related disorders
WO2005092854A1 (en) 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
EP2086935A1 (de) 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
CN101563324A (zh) 2006-12-22 2009-10-21 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
EP2178870B1 (en) 2007-08-17 2018-09-19 LG Chem, Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
PL2501704T3 (pl) 2009-11-16 2014-02-28 Lilly Co Eli Spiropiperydynowe związki jako antagoniści receptora ORL-1
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
WO2016029310A1 (en) 2014-08-27 2016-03-03 The Governing Council Of The University Of Toronto Cannabinoid type 1 receptor modulators
BR112017007178A2 (pt) 2014-10-08 2017-12-19 Ass Francaise Contre Les Myopathies compostos de aminopiridina úteis como inibidores de prenilação de proteína
JP2017535545A (ja) 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−1,4’−ピペリジン化合物
HRP20210472T1 (hr) 2015-08-27 2021-05-14 Pfizer Inc. Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4
CN108884096B (zh) 2016-02-08 2022-03-22 豪夫迈·罗氏有限公司 作为ddr1抑制剂的螺二氢吲哚酮
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
UY37956A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
EP3787669A4 (en) 2018-04-30 2022-03-30 The Trustees of Indiana University COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
PH12022551102A1 (en) 2019-11-08 2023-11-20 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof
US12698266B2 (en) 2019-12-19 2026-08-04 Casma Therapeutics, Inc. TRPML modulators
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
EP4114385A1 (en) 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
CA3171950A1 (en) 2020-04-22 2021-10-28 David William Sheppard Collagen 1 translation inhibitors and methods of use thereof
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
US20230014907A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
PL4129989T3 (pl) 2020-08-26 2025-02-24 Haisco Pharmaceuticals Pte. Ltd. Pochodna nitrilu działająca jako inhibitor dipeptydylopeptydazy 1 i jej zastosowanie
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
KR20240051990A (ko) 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
AU2022401847A1 (en) 2021-11-30 2024-06-06 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
CN119343353A (zh) 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
EP4476199A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
WO2023154314A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Spiro piperidine derivatives as inhibitors of apol1 and methods of using same
EP4476228A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Also Published As

Publication number Publication date
US20240368180A1 (en) 2024-11-07
LT4204423T (lt) 2026-08-10
JP7743504B2 (ja) 2025-09-24
WO2022047031A1 (en) 2022-03-03
UY39395A (es) 2022-03-31
IL300298B1 (en) 2025-02-01
US12421249B2 (en) 2025-09-23
CR20230132A (es) 2023-06-27
FI4204423T3 (fi) 2026-07-15
DOP2023000042A (es) 2023-07-09
ECSP23020167A (es) 2023-12-29
PE20231106A1 (es) 2023-07-19
PT4204423T (pt) 2026-07-20
MA61088B1 (fr) 2026-06-30
TWI915407B (zh) 2026-02-21
IL300298B2 (en) 2025-06-01
SA523442662B1 (ar) 2025-05-26
CN116547287A (zh) 2023-08-04
JOP20230035A1 (ar) 2023-02-14
JP2023539194A (ja) 2023-09-13
MX2023002269A (es) 2023-05-16
AR123355A1 (es) 2022-11-23
JP2025183328A (ja) 2025-12-16
IL300298A (en) 2023-04-01
KR20230057386A (ko) 2023-04-28
EP4204423A1 (en) 2023-07-05
EP4204423B1 (en) 2026-06-03
CL2023000536A1 (es) 2023-09-08
CA3190609A1 (en) 2022-03-03
TW202227456A (zh) 2022-07-16
US11866446B2 (en) 2024-01-09
CN116547287B (zh) 2025-09-26
CO2023003026A2 (es) 2023-03-17
IL318169A (en) 2025-03-01
BR112023003423A2 (pt) 2023-03-21
US20220106327A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
US12421249B2 (en) Inhibitors of APOL1 and methods of using same
EP3889154A1 (en) Heterocyclic compound intermediate, preparation method therefor and application thereof
JP7017521B2 (ja) アクチビン受容体様キナーゼの阻害剤
CA2930414C (en) Tetrahydroquinoline compositions as bet bromodomain inhibitors
RU2679914C1 (ru) Конденсированные трициклические производные имидазола в качестве модуляторов активности tnf
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
AU2014221489B2 (en) Tricyclic compound and use thereof
JP2025505647A (ja) Apol1阻害剤としての2-メチル-4’,5’-ジヒドロピロ[ピペリジン-4,7’-チエノ[2,3-c]ピラン]誘導体、およびそれを使用する方法
EP4476228A1 (en) 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
AU2014221775A1 (en) TETRAHYDROIMIDAZO[1,5-d][1,4]OXAZEPINE DERIVATIVE
CA2935071A1 (en) Piperidine-dione derivatives
AU2012320582A1 (en) Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
CN118632850A (zh) Apol1的螺环抑制剂和其使用方法
IL259862A (en) Inhibitors of bruton's tyrosine kinase and methods of their use
EP4423068B1 (en) Rxfp1 agonists
RU2740008C2 (ru) Фармацевтическое средство, содержащее ингибитор натрийзависимого переносчика фосфата
JP2025530793A (ja) Egfr阻害剤及びその使用
OA21175A (en) Inhibitors of APOL1 and methods of using same.
WO2026093401A1 (en) Macrocyclic compounds and pharmaceutical compositions thereof for the treatment of proliferative diseases
EA044922B1 (ru) ИНГИБИТОРЫ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ KEAP1-Nrf2
HK1228786A1 (en) Tetrahydroquinoline compositions as bet bromodomain inhibitors
HK1228786B (en) Tetrahydroquinoline compositions as bet bromodomain inhibitors